Macquarie Group LTD Mei Pharma, Inc. Transaction History

Macquarie Group LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 15, 2019	BUY	$1.92 - $4.1 $412,800 - $881,499	215,000 Added 55.84%	600,000 $1.58 Million
Q3 2018 Nov 15, 2018	BUY	$3.39 - $4.61 $423,750 - $576,250	125,000 Added 48.08%	385,000 $1.66 Million
Q2 2018 Aug 14, 2018	BUY	$1.89 - $4.95 $491,400 - $1.29 Million	260,000 New	260,000 $1.02 Million
Q1 2018 May 11, 2018	SELL	$2.06 - $2.38 $198,110 - $228,884	-96,170 Closed	0 $0
Q4 2017 Feb 15, 2018	SELL	$1.91 - $2.83 $34,485 - $51,095	-18,055 Reduced 15.81%	96,170 $202,000

Q3 2017 Nov 08, 2017	BUY	$2.44 - $2.91 $278,709 - $332,394	114,225	114,225 $306,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $372M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.